Peer-Review Report of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4681)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Jan 15, 2025 (publication date) through Feb 14, 2026
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Oncology
ISSN
1948-5204
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| Wu FD, Zhou HF, Yang W, Zhu D, Wu BF, Shi HB, Liu S, Zhou WZ. Transarterial chemoembolization combined with lenvatinib and sintilimab vs lenvatinib alone in intermediate-advanced hepatocellular carcinoma. World J Gastrointest Oncol 2025; 17(1): 96267 [PMID: 39817120 DOI: 10.4251/wjgo.v17.i1.96267] |
|
|
|
| ©2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA | |
| For: | Wu FD, Zhou HF, Yang W, Zhu D, Wu BF, Shi HB, Liu S, Zhou WZ. Transarterial chemoembolization combined with lenvatinib and sintilimab vs lenvatinib alone in intermediate-advanced hepatocellular carcinoma. World J Gastrointest Oncol 2025; 17(1): 96267 [PMID: 39817120 DOI: 10.4251/wjgo.v17.i1.96267] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5204/full/v17/i1/96267.htm |
| Number | Citing Articles |
| 1 |
|
| 2 |
Qian Wang. Targeted therapy for liver cancer: Current status and future directions. BioImpacts 2025; 15: 32630 doi: 10.34172/bi.32630
|
| 3 |
Ying Chen, Linglin Fu, Ping Song, Yinuo Tan, Yuqi Jin. Donafenib intolerance in hepatocellular carcinoma: severe hand–foot skin reaction and successful switch to lenvatinib – a case report and literature review. Frontiers in Oncology 2025; 15 doi: 10.3389/fonc.2025.1728098
|
| 4 |
Houxiang Ya, Kai Wang, Huixia Qin, Yi Zhou, Hesheng Lin, Chengyuan Liu, Kaiwen Jiang, Jing Gu, Shuqun Li. Comparing of Efficacy and Safety Between Sintilimab Plus IBI305 and PD‐1 Inhibitor Plus TKIs in Combination of TACE for uHCC. Liver International 2026; 46(3) doi: 10.1111/liv.70551
|
| 5 |
Yongfa Lei, Xiaotian Liang, Hua Zhu, Jin Wang, Xiaochen Zhang, Siliang Duan, Weiming Liang. Efficacy and safety of lenvatinib plus transarterial chemoembolization with or without programmed death-1 inhibitors in the treatment of intermediate or advanced hepatocellular carcinoma: a systematic review and meta-analysis. Frontiers in Immunology 2025; 16 doi: 10.3389/fimmu.2025.1586914
|
| 6 |
Jingting Su, Yuejiao Su, Rongyun Mai, Xing Gao, Shizhou Li, Dandan Zeng, Weijie Cen, Zhenbo Huang, Xiaoqing Li, Haoyu Zeng, Wenbing Li, Can Zeng, Tianzhun Wu, Kaixiang Mo, Jiazhou Ye, Yan Lin, Rong Liang. Comparative efficacy of combination regimens based on interventional therapy and immune checkpoint inhibitors (ICIs) in patients with intermediate- and advanced-stage hepatocellular carcinoma: a systematic review, meta-analysis, and network meta-analysis. Cancer Immunology, Immunotherapy 2026; 75(3) doi: 10.1007/s00262-025-04251-5
|
| 7 |
Kailin Ye, Jiale Zhou, Jie Lin, Yongzhi Li, Yansong Luo, Fei Xie. Efficacy of TACE plus tyrosine kinase inhibitors and immune checkpoint inhibitors in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Frontiers in Oncology 2025; 15 doi: 10.3389/fonc.2025.1707622
|